HMN 2025: How Lower dexamethasone dose doesn’t impair survival in a number of myeloma

For sufferers with newly recognized a number of myeloma (NDMM) receiving dexamethasone induction, dose reductions don’t negatively affect survival, in accordance with a research published on-line Jan. 2 in Blood.

Rahul Banerjee, M.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues carried out a secondary pooled evaluation of the SWOG 0777 and SWOG 1211 research, which examined lenalidomide and dexamethasone alone, with or with out bortezomib and with or with out elotuzumab for NDMM. In all arms, the deliberate dexamethasone depth was 40 to 60 mg weekly. Patients had been categorised as full-dose dexamethasone all through induction (FD-DEX) or lowered-dose dexamethasone or discontinuation (LD-DEX), permitted for grade 3+ toxicities per each research protocols.

The LD-DEX group included 373 sufferers (69%) of the 541 evaluated. The researchers discovered that progression-free survival (PFS) and total survival (OS) didn’t differ between the FD-DEX and LD-DEX teams. In the multivariate fashions, predictors of PFS and OS had been remedy arm, age 70 years or older, and thrombocytopenia.

“Dexamethasone dose reductions <40 to 60 mg per week are fairly frequent even within the setting of scientific trials,” the authors write. “These dose reductions don’t seem to negatively affect PFS or OS. We encourage future trials to research lowered-dose dexamethasone methods prospectively, both at remedy onset or inside a number of cycles of remedy initiation.”

Several authors disclosed ties to the biopharmaceutical business.

© 2025 .